Filing Flows › Health Care › Mereo BioPharma Group (MREO)
Mereo BioPharma Group (MREO) earnings and revenue breakdown
Latest: Q2 2025 · 10-Q filed Aug 12, 2025 · Mereo BioPharma Group (MREO) Q2 2025 earnings results →
Mereo BioPharma Group made $500K in Q2 2025. Operating margin n/m, net loss $14.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $500K in Q2 2025.
Operating costs exceeded revenue by $10.5M, an operating margin of -2099.8%. The quarter ended with a net loss of $14.6M.
Operating cash flow was −$7.7M. Non-cash charges added back $162K of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items added $4.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2025 | 10-Q | Aug 12, 2025 | $500K | — | n/m | −$14.6M | −$7.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Mereo BioPharma Group
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S.
In its own words, from its 8-K, filed Aug 11, 2026.
Mereo BioPharma Group against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MREO Mereo BioPharma Group | Q2 2025 | $500K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Mereo BioPharma Group 10-Q on SEC EDGAR · CIK 1719714 · Pharmaceutical Preparations
13F: who owns MREO and who is buying
More on MREO
History
Every quarter: Q2 2025 results